NCT04047862 2025-08-22
Study of Ociperlimab (BGB-A1217) in Combination With Tislelizumab in Advanced Solid Tumors
BeiGene
Phase 1 Completed
Clinical Trials
7 trialsNCT04716634 2025-03-25
Efficacy and Safety of Tislelizumab in Combination With Fruquintinib in Participants With Selected Solid Tumors
BeiGene
Phase 2 Completed
NCT03666143 2024-11-04
A Phase 1b Study to Assess Sitravatinib in Combination With Tislelizumab in Participants With Advanced Solid Tumors
BeiGene
Phase 1 Completed
NCT04068519 2024-10-26
Study Investigating Safety, Tolerability, Pharmacokinetics (PK) and Antitumor Activities of Anti-PD-1 (Programmed Death-1) Monoclonal Antibody
BeiGene
Phase 1/2 Completed
NCT05508100 2024-05-24
Dose Confirmation and Dose Expansion Phase 1 Study of IO-108 and IO-108 + Anti-PD-1 in Solid Tumors
Immune-Onc Therapeutics
Phase 1 Completed
NCT05809336 2023-04-12
Gut Microbial Metabolites Inosine Combined With PD-1/PD-L1 Inhibitor for Patients With Malignant Advanced Solid Tumors
Beijing Friendship Hospital
Phase 2/3 Completed
NCT02660034 2021-12-06
The Safety, Pharmacokinetics and Antitumor Activity of BGB-A317 in Combination With BGB-290 in Participants With Advanced Solid Tumors
BeiGene
Phase 1 Completed